Across its top 1 institutional holders, OVASUSD's holder base skews toward high-concentration, low-turnover investors on average (avg. concentration score 93/100, avg. turnover score 45/100).
Quarterly Activity
Recent Activity
+$0.0
Total Buy Value
$0.0
Total Sell Value
New buy0
Trim0
Add0
Sold out0
0
Net Buyers
0
Net Sellers
Smart Money Convergence
OVASUSD does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
No Form 8-K filings for this ticker
CUSIP
87978U108
FAQ
Who are the top institutional investors holding TEMPEST THERAPEUTICS INC (OVASUSD)?
Major stakeholders currently include Versant Venture Management, LLC ($442.4K). Based on the latest 13F filings, there are a total of 1 tracked investment funds and institutions maintaining positions in OVASUSD.
What is the overall institutional sentiment toward OVASUSD recently?
Institutional sentiment appears Neutral. During the most recent reporting quarter, the stock experienced no significant net capital flow from tracked managers.
Which institutions have been selling or reducing their OVASUSD positions?
In the latest period, no tracked funds trimmed or exited their positions in OVASUSD.
Are there any notable investors adding OVASUSD to their portfolios?
No tracked institutions opened new positions or added to their existing holdings in OVASUSD during the last reporting period.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter